Clinical Practice Guidelines for Intraductal Papilloma: Chinese Society of Breast Surgery (CSBrS)Practice Guidelines 2021

Title: Clinical Practice Guidelines for Intraductal Papilloma: Chinese Society of Breast Surgery (CSBrS)Practice Guidelines 2021
Edition: Original
Classification: Standard guideline
Field: Comprehensive guideline
Countries and regions: China
Guidelines users: clinicians specializing in breast diseases in China.
Evidence classification method: Grading of Recommendations Assessment, Development and Evaluation (GRADE) system
Development unit: 中华医学会外科学分会乳腺外科学组
Registration time: 2021-06-02
Registration number: IPGRP-2021CN137
Purpose of the guideline: Intraductal papilloma of the breast is relatively common, accounting for 5.3% of all benign breast diseases.[1] However, relapse readily occurs with pathological changes such as atypical ductal hyperplasia (ADH) and canceration, and the rate of underestimation of biopsy diagnosis is high . [2 3]Therefore, specific considerations are required for the diagnosis and treatment methods of intraductal papilloma, and some clinical problems with these methods remain controversial. To standardize the diagnosis and treatment of intraductal papilloma of the breast and provide a reference for the clinical work of breast specialists, Chinese Society of Breast Surgery has determined the key clinical issues of the clinical practice guidelines for intraductal papilloma of the breast through a literature search and expert discussion. The relevant evidence was evaluated with reference to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, and the Clinical Practice Guidelines for Intraductal Papilloma: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2021 was formulated to provide a reference for the clinical work of breast surgeons in China.